New immune cocktail takes on deadly mesothelioma

NCT ID NCT07514793

Not yet recruiting Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding two immune-boosting drugs (iparomlimab and tovorilimab) to standard chemotherapy and bevacizumab can shrink tumors in people with advanced mesothelioma who have not had prior treatment. About 37 participants will receive the combination every three weeks. The main goal is to see how many patients respond, with secondary aims of controlling the disease and prolonging response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Iparomlimab and tovorilimab (immune-boosting drugs) plus bevacizumab (anti-angiogenic drug) and chemotherapy (pemetrexed and cisplatin or carboplatin)
What this could lead to: If successful, this combination could offer a new first-line treatment option that shrinks tumors and controls advanced mesothelioma for longer.
What could go wrong: This is a small, early-phase trial with only 37 participants and no comparison group. The added drugs may increase side effects without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MESOTHELIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant mesothelioma mesothelioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MESOTHELIOMA

Contacts and locations

Locations

Fudan university cancer hospital

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.